Alexion and Complement Pharma Announce Partnership to Co-Develop Pre-Clinical Complement Inhibitor for Neurodegenerative Disorders Collaboration provides opportunity to expand on Alexion’s two decades ...
- Agreement provides Alexion with exclusive worldwide licenses for one preclinical target, with option for up to three additional targets, in the complement pathway - - Zealand Pharma to receive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results